Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7878838 | 0.83 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL1507155 | 0.77 | PRKCA (0.35) | ALDH1A1PRKCA | |
| SCHEMBL1507276 | 0.74 | PRKCA (0.37) | ALDH1A1PRKCA | |
| SCHEMBL5694626 | 0.73 | ALDH1A1 (0.42) | ALDH1A1TSHRMAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL638234 | 0.71 | PRKCA (0.35) | PRKCA | |
| SCHEMBL65267 | 0.71 | ELANE (0.40) | ALDH1A1ELANETSHRPRKCA | |
| SCHEMBL779254 | 0.70 | ALDH1A1 (0.38) | ALDH1A1ELANEPRKCASMN1; SMN2 | |
| SCHEMBL7989586 | 0.70 | ELANE (0.34) | ALDH1A1ELANEPRKCA | |
| Ammonia Solution, Strong SCHEMBL25421893 | 0.68 | ELANE (0.39) | ALDH1A1ELANETSHRPRKCA | |
| SCHEMBL7026388 | 0.68 | ELANE (0.39) | ALDH1A1ELANETSHRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249076-A1 | PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20060287283-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20050137174-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249076-A1 | PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS | TET3, TET1, TPMT | ALDH1A1 3508/4885ELANE 3004/4885TSHR 2696/4885 |
| US-20050137174-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | TET3, TET1, TPMT | ALDH1A1 3508/4885ELANE 3004/4885TSHR 2696/4885 |
| US-20060287283-A1 | Prodrugs of 9-aminomethyl tetracycline compounds | TET3, TET1, TPMT | ALDH1A1 3508/4885ELANE 3004/4885TSHR 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.